Hypera S.A (HYPE3) - Net Assets
Based on the latest financial reports, Hypera S.A (HYPE3) has net assets worth R$14.12 Billion BRL (≈ $2.77 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$29.50 Billion ≈ $5.79 Billion USD) and total liabilities (R$15.38 Billion ≈ $3.02 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Hypera S.A assets under control for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R$14.12 Billion |
| % of Total Assets | 47.87% |
| Annual Growth Rate | 33.24% |
| 5-Year Change | 27.36% |
| 10-Year Change | 43.82% |
| Growth Volatility | 379.54 |
Hypera S.A - Net Assets Trend (2005–2025)
This chart illustrates how Hypera S.A's net assets have evolved over time, based on quarterly financial data. Check HYPE3 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Hypera S.A (2005–2025)
The table below shows the annual net assets of Hypera S.A from 2005 to 2025. For live valuation and market cap data, see HYPE3 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | R$12.52 Billion ≈ $2.46 Billion |
+3.49% |
| 2024-12-31 | R$12.10 Billion ≈ $2.37 Billion |
+5.07% |
| 2023-12-31 | R$11.52 Billion ≈ $2.26 Billion |
+8.09% |
| 2022-12-31 | R$10.66 Billion ≈ $2.09 Billion |
+8.36% |
| 2021-12-31 | R$9.83 Billion ≈ $1.93 Billion |
+6.41% |
| 2020-12-31 | R$9.24 Billion ≈ $1.81 Billion |
+6.09% |
| 2019-12-31 | R$8.71 Billion ≈ $1.71 Billion |
+5.35% |
| 2018-12-31 | R$8.27 Billion ≈ $1.62 Billion |
+6.85% |
| 2017-12-31 | R$7.74 Billion ≈ $1.52 Billion |
-11.15% |
| 2016-12-31 | R$8.71 Billion ≈ $1.71 Billion |
+8.44% |
| 2015-12-31 | R$8.03 Billion ≈ $1.58 Billion |
+7.42% |
| 2014-12-31 | R$7.48 Billion ≈ $1.47 Billion |
+5.61% |
| 2013-12-31 | R$7.08 Billion ≈ $1.39 Billion |
+3.06% |
| 2012-12-31 | R$6.87 Billion ≈ $1.35 Billion |
+3.35% |
| 2011-12-31 | R$6.65 Billion ≈ $1.30 Billion |
+31.37% |
| 2010-12-31 | R$5.06 Billion ≈ $992.69 Million |
+48.02% |
| 2009-12-31 | R$3.42 Billion ≈ $670.62 Million |
+78.33% |
| 2008-12-31 | R$1.92 Billion ≈ $376.06 Million |
+176.68% |
| 2007-12-31 | R$692.69 Million ≈ $135.92 Million |
+1752.11% |
| 2006-12-31 | R$37.40 Million ≈ $7.34 Million |
-7.20% |
| 2005-12-31 | R$40.30 Million ≈ $7.91 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hypera S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 108127700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | R$1.07 Billion | 8.51% |
| Common Stock | R$9.71 Billion | 77.51% |
| Other Comprehensive Income | R$1.76 Billion | 14.08% |
| Total Equity | R$12.52 Billion | 100.00% |
Hypera S.A Competitors by Market Cap
The table below lists competitors of Hypera S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bufab Holding AB
ST:BUFAB
|
$2.78 Billion |
|
Aura Minerals Inc
TO:ORA
|
$2.78 Billion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
$2.78 Billion |
|
Celldex Therapeutics Inc
NASDAQ:CLDX
|
$2.78 Billion |
|
ABL Bio Inc
KQ:298380
|
$2.78 Billion |
|
California Water Service Group
NYSE:CWT
|
$2.77 Billion |
|
IHS Holding Ltd
NYSE:IHS
|
$2.77 Billion |
|
Inner Mongolia First Machinery Group Co Ltd
SHG:600967
|
$2.77 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hypera S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,096,281,000 to 12,522,029,000, a change of 425,748,000 (3.5%).
- Net income of 1,195,369,000 contributed positively to equity growth.
- Dividend payments of 627,785,000 reduced retained earnings.
- Share repurchases of 23,088,000 reduced equity.
- New share issuances of 10,549,000 increased equity.
- Other comprehensive income increased equity by 858,913,999.
- Other factors decreased equity by 988,210,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R$1.20 Billion | +9.55% |
| Dividends Paid | R$627.78 Million | -5.01% |
| Share Repurchases | R$23.09 Million | -0.18% |
| Share Issuances | R$10.55 Million | +0.08% |
| Other Comprehensive Income | R$858.91 Million | +6.86% |
| Other Changes | R$-988.21 Million | -7.89% |
| Total Change | R$- | 3.52% |
Book Value vs Market Value Analysis
This analysis compares Hypera S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.03x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 158.26x to 1.03x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | R$0.13 | R$20.10 | x |
| 2006-12-31 | R$0.12 | R$20.10 | x |
| 2007-12-31 | R$2.18 | R$20.10 | x |
| 2008-12-31 | R$4.83 | R$20.10 | x |
| 2009-12-31 | R$7.93 | R$20.10 | x |
| 2010-12-31 | R$9.02 | R$20.10 | x |
| 2011-12-31 | R$9.95 | R$20.10 | x |
| 2012-12-31 | R$10.23 | R$20.10 | x |
| 2013-12-31 | R$10.97 | R$20.10 | x |
| 2014-12-31 | R$11.61 | R$20.10 | x |
| 2015-12-31 | R$12.47 | R$20.10 | x |
| 2016-12-31 | R$13.57 | R$20.10 | x |
| 2017-12-31 | R$12.16 | R$20.10 | x |
| 2018-12-31 | R$12.93 | R$20.10 | x |
| 2019-12-31 | R$13.61 | R$20.10 | x |
| 2020-12-31 | R$14.48 | R$20.10 | x |
| 2021-12-31 | R$15.37 | R$20.10 | x |
| 2022-12-31 | R$16.66 | R$20.10 | x |
| 2023-12-31 | R$18.04 | R$20.10 | x |
| 2024-12-31 | R$18.96 | R$20.10 | x |
| 2025-12-31 | R$19.47 | R$20.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hypera S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.55%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.53%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 2.28x
- Recent ROE (9.55%) is below the historical average (10.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 76.92% | 8.94% | 1.35x | 6.39x | R$26.97 Million |
| 2006 | -7.84% | -0.77% | 1.19x | 8.54x | R$-6.67 Million |
| 2007 | 6.09% | 3.97% | 0.54x | 2.85x | R$-27.03 Million |
| 2008 | -10.85% | -15.59% | 0.37x | 1.86x | R$-399.53 Million |
| 2009 | 8.50% | 14.85% | 0.32x | 1.77x | R$-51.62 Million |
| 2010 | 5.18% | 9.38% | 0.28x | 1.97x | R$-244.01 Million |
| 2011 | -0.82% | -1.64% | 0.25x | 2.01x | R$-719.24 Million |
| 2012 | 2.97% | 5.26% | 0.31x | 1.84x | R$-482.92 Million |
| 2013 | 3.63% | 6.03% | 0.34x | 1.77x | R$-451.14 Million |
| 2014 | 5.39% | 14.55% | 0.20x | 1.86x | R$-344.90 Million |
| 2015 | 6.97% | 18.94% | 0.19x | 1.97x | R$-243.17 Million |
| 2016 | 13.52% | 36.48% | 0.28x | 1.31x | R$306.90 Million |
| 2017 | 12.47% | 27.57% | 0.35x | 1.31x | R$191.17 Million |
| 2018 | 13.66% | 30.33% | 0.35x | 1.28x | R$302.83 Million |
| 2019 | 13.36% | 35.33% | 0.28x | 1.37x | R$293.03 Million |
| 2020 | 14.02% | 31.67% | 0.24x | 1.87x | R$371.04 Million |
| 2021 | 13.54% | 22.40% | 0.30x | 2.02x | R$347.55 Million |
| 2022 | 15.94% | 22.48% | 0.32x | 2.23x | R$632.12 Million |
| 2023 | 14.32% | 20.82% | 0.32x | 2.13x | R$497.55 Million |
| 2024 | 11.09% | 18.02% | 0.30x | 2.03x | R$131.36 Million |
| 2025 | 9.55% | 15.53% | 0.27x | 2.28x | R$-56.83 Million |
Industry Comparison
This section compares Hypera S.A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $376,334,000
- Average return on equity (ROE) among peers: -1.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hypera S.A (HYPE3) | R$14.12 Billion | 76.92% | 1.09x | $2.78 Billion |
| Ouro Fino Saúde Animal Participações S.A (OFSA3) | $376.33 Million | -1.38% | 1.06x | $273.25 Million |
About Hypera S.A
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Co… Read more